Stockscreener 앱 받기
104.80
0.46%
0.48
시장 영업 전:
105.01
0.21
+0.20%
Axsome Therapeutics Inc 주식(AXSM)의 최신 뉴스
Equities Analysts Issue Forecasts for AXSM Q3 Earnings - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q2 2025 Earnings Call Transcript - MSN
XTX Topco Ltd Sells 9,794 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
FY2026 EPS Estimates for AXSM Increased by Cantor Fitzgerald - MarketBeat
HC Wainwright Issues Pessimistic Estimate for AXSM Earnings - MarketBeat
TD Asset Management Inc Takes Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome outlines late-stage pipeline advancements and targets cash flow positivity amid 72% revenue growth - MSN
Federated Hermes Inc. Makes New $3.03 Million Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
HC Wainwright Brokers Lower Earnings Estimates for AXSM - MarketBeat
FY2026 EPS Estimates for AXSM Decreased by Cantor Fitzgerald - MarketBeat
Leerink Partnrs Issues Optimistic Estimate for AXSM Earnings - MarketBeat
J. Safra Sarasin Holding AG Makes New $1.13 Million Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics’ Earnings Call Highlights Robust Growth - The Globe and Mail
Axsome Therapeutics Jumps 5% as Q2 Revenue Surpasses Projections - MSN
Axsome Therapeutics: Strong Sales Performance and Promising Growth Trajectory Reinforce Buy Recommendation - TipRanks
Axsome Therapeutics: Strong Growth Prospects and Strategic Investments Justify Buy Rating - TipRanks
AXSM Q2 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y - MSN
Axsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $176.00 - MarketBeat
Royal Bank Of Canada Issues Positive Forecast for Axsome Therapeutics (NASDAQ:AXSM) Stock Price - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Axsome Therapeutics Analysts Increase Their Forecasts After Q2 Earnings - 富途牛牛
Analysts Are Bullish on Top Healthcare Stocks: Mind Medicine (MNMD), Axsome Therapeutics (AXSM) - The Globe and Mail
Shareholders Have Faith in Loss-making Axsome Therapeutics (NASDAQ:AXSM) as Stock Climbs 6.1% in Past Week, Taking Three-year Gain to 146% - 富途牛牛
Axsome Therapeutics: BofA Securities Reiterates Buy Rating, Raises PT to $176. - AInvest
RBC Capital Reiterates Outperform on Axsome Therapeutics, Raises PT to $189 - AInvest
Needham & Company LLC Reaffirms Buy Rating for Axsome Therapeutics (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics Reports Strong Q2 2025 Performance - The Globe and Mail
Axsome Therapeutics (NASDAQ:AXSM) Announces Quarterly Earnings Results, Beats Estimates By $0.12 EPS - MarketBeat
Axsome: Q2 Earnings Snapshot - New Haven Register
Axsome Therapeutics Inc (AXSM) Q2 2025 Earnings Call Highlights: Robust Revenue Growth and ... By GuruFocus - Investing.com Canada
Axsome Therapeutics Reports Strong Q2 2025 Growth - TipRanks
Axsome Therapeutics: Strong Sales Performance and Strategic Growth Initiatives Drive Buy Rating - TipRanks
Analysts bullish on AbbVie, Axsome Therapeutics, and GE Healthcare Technologies Inc. - AInvest
Axsome Therapeutics, Inc. SEC 10-Q Report - TradingView
Axsome Achieves 72% Revenue Growth, Sets Sights on Cash Flow Positivity - AInvest
Axsome Therapeutics, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:AXSM) - Seeking Alpha
Axsome Therapeutics (AXSM): Is Now the Time to Buy After a Strong Q2 Earnings Beat? - AInvest
Axsome (AXSM) Q2 Revenue Soars 72% - sharewise.com
Here's What Key Metrics Tell Us About Axsome (AXSM) Q2 Earnings - Yahoo Finance
Earnings call transcript: Axsome Therapeutics beats Q2 2025 forecasts - Investing.com
Axsome Therapeutics, Wayfair, IDEXX Laboratories - TradingView
Axsome Therapeutics Reports Narrowed Q2 Losses, Exceeds Revenue Expectations - IndexBox
Axsome Q2 2025 slides: revenue surges 72% YoY, pipeline advances on track - Investing.com UK
Axsome Therapeutics (AXSM) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Axsome Therapeutics shares 5% surge as second quarter revenue beats expectations By Investing.com - Investing.com South Africa
Axsome Therapeutics shares 5% surge as second quarter revenue beats expectations - Investing.com
Axsome Therapeutics Inc earnings beat by $0.09, revenue topped estimates - Investing.com Australia
Axsome Therapeutics Posts Strong Growth As AUVELITY Drives Sales - Finimize
Axsome Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update - The Manila Times
0.24%
3.39%
자본화:
|
볼륨(24시간):